Literature DB >> 21769537

Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis.

Jorge Vila Arteaga1, Mayerling Mercedes Suriano, Oana Stirbu.   

Abstract

The aim of this article is to report a case of Aspergillus chorioretinitis successfully treated with intravitreal voriconazole based on an interventional case report. An immunodeficient patient, 34 years old, receiving systemic antifungal treatment for 1 month for invasive aspergillosis with necrotizing pneumonia and brain metastasis, who presented with blurred vision in his left eye. Visual acuity (VA) was 20/20 in his right eye, and 8/20 in his left eye. Ophthalmological examination showed a paramacular nodular yellowish chorioretinal lesion with intraretinal hemorrhages, in the absence of vitritis or anterior uveitis. The patient was treated with one dose of intravitreal voriconazole (100 μg/0.1 ml). One week after the intravitreal injection, the patient's VA was 10/20, the retinal lesions had diminished, and the hemorrhages had disappeared. At 3-month follow-up, his AV was 20/20 with a residual retinal scar. The significant and rapid improvement in this patient suggests that early injection of intravitreal voriconazole may be the first therapeutic option in Aspergillus chorioretinitis, obviating the need for vitrectomy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769537     DOI: 10.1007/s10792-011-9455-7

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  12 in total

Review 1.  Update on antifungal agents for paediatric patients.

Authors:  A H Groll; A Tragiannidis
Journal:  Clin Microbiol Infect       Date:  2010-09       Impact factor: 8.067

2.  [Endogenous fungal endophthalmitis: results of antifungal treatment with and without vitrectomy].

Authors:  M Bagnoud; E Baglivo; J Hengstler; A B Safran; C J Pournaras; P Leuenberger
Journal:  Klin Monbl Augenheilkd       Date:  2001-05       Impact factor: 0.700

3.  Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series.

Authors:  Parveen Sen; Lingam Gopal; Pratik Ranjan Sen
Journal:  Retina       Date:  2006-10       Impact factor: 4.256

4.  Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.

Authors:  Michal Kramer; Mordechai R Kramer; Hannah Blau; Jihad Bishara; Ruth Axer-Siegel; Dov Weinberger
Journal:  Ophthalmology       Date:  2006-05-19       Impact factor: 12.079

5.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 6.  Voriconazole: therapeutic review of a new azole antifungal.

Authors:  Raoul Herbrecht
Journal:  Expert Rev Anti Infect Ther       Date:  2004-08       Impact factor: 5.091

7.  Safety of intravitreal voriconazole: electroretinographic and histopathologic studies.

Authors:  Hua Gao; Mark Pennesi; Kekul Shah; Xiaoxi Qiao; Seenu M Hariprasad; William F Mieler; Samuel M Wu; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2003

8.  Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis.

Authors:  Ingrid U Scott; Vanessa Cruz-Villegas; Harry W Flynn; Darlene Miller
Journal:  Am J Ophthalmol       Date:  2004-03       Impact factor: 5.258

9.  Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz; Hua Gao; Judy E Kim; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2004-01

10.  Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole.

Authors:  Richard C Lin; Neeraj Sanduja; Seenu M Hariprasad
Journal:  J Ocul Pharmacol Ther       Date:  2008-04       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.